TScan Therapeutics’ (TCRX) “Overweight” Rating Reaffirmed at Morgan Stanley

Morgan Stanley restated their overweight rating on shares of TScan Therapeutics (NASDAQ:TCRX) in a research report report published on Friday morning,Benzinga reports. Morgan Stanley currently has a $10.00 price objective on the stock.

Several other brokerages also recently weighed in on TCRX. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price target on shares of TScan Therapeutics in a report on Thursday, March 6th. Needham & Company LLC decreased their price target on TScan Therapeutics from $11.00 to $9.00 and set a “buy” rating for the company in a report on Wednesday, March 5th. Barclays decreased their price target on TScan Therapeutics from $14.00 to $3.00 and set an “overweight” rating for the company in a report on Friday, March 7th. Finally, Wedbush reaffirmed an “outperform” rating and set a $7.00 price target on shares of TScan Therapeutics in a report on Wednesday, March 5th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $9.33.

TScan Therapeutics Stock Performance

Shares of TCRX opened at $1.74 on Friday. The company has a current ratio of 9.56, a quick ratio of 9.56 and a debt-to-equity ratio of 0.13. The firm has a market cap of $92.87 million, a PE ratio of -1.64 and a beta of 0.91. The company’s 50 day simple moving average is $2.28 and its 200-day simple moving average is $3.88. TScan Therapeutics has a 12-month low of $1.71 and a 12-month high of $9.69.

TScan Therapeutics (NASDAQ:TCRX) last announced its earnings results on Wednesday, March 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.02). The business had revenue of $0.67 million for the quarter, compared to analysts’ expectations of $1.43 million. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. As a group, equities analysts predict that TScan Therapeutics will post -1.12 EPS for the current year.

Institutional Trading of TScan Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. purchased a new stake in TScan Therapeutics during the 4th quarter worth about $32,000. Prudential Financial Inc. purchased a new stake in TScan Therapeutics during the 4th quarter worth about $32,000. ProShare Advisors LLC purchased a new stake in TScan Therapeutics during the 4th quarter worth about $40,000. Squarepoint Ops LLC purchased a new stake in TScan Therapeutics during the 4th quarter worth about $59,000. Finally, Wells Fargo & Company MN increased its position in TScan Therapeutics by 41.1% during the 4th quarter. Wells Fargo & Company MN now owns 19,540 shares of the company’s stock worth $59,000 after purchasing an additional 5,694 shares in the last quarter. Hedge funds and other institutional investors own 82.83% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.